Contineum Therapeutics, Inc. Number of Reportable Segments
Contineum Therapeutics, Inc. (CTNM) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-07-30
- Contineum Therapeutics, Inc. number of reportable segments for the quarter ending 2025-06-30 was 100.00%.
- Contineum Therapeutics, Inc. number of reportable segments for the quarter ending 2025-03-31 was 100.00%.
- Contineum Therapeutics, Inc. number of reportable segments for fiscal 2024 was 100.00%.
pure
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 12 month |
|---|---|---|
| 2025-06-30 | 100.00% 10-Q · filed 2025-10-30 | |
| 2025-03-31 | 100.00% 10-Q · filed 2025-05-14 | |
| 2024-12-31 | 100.00% 10-K · filed 2025-03-06 |
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |